Toll Free: 1-888-928-9744

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 274 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016', provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
- The report reviews pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Relapsed Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects
- The report assesses Relapsed Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 8 Therapeutics Development 9 Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 9 Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10 Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11 Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17 Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20 Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21 4SC AG 21 AbbVie Inc. 22 Astellas Pharma Inc. 23 Astex Pharmaceuticals, Inc. 24 AstraZeneca Plc 25 Boehringer Ingelheim GmbH 26 Bristol-Myers Squibb Company 27 Celgene Corporation 28 Cyclacel Pharmaceuticals, Inc. 29 Emergent BioSolutions Inc. 30 F. Hoffmann-La Roche Ltd. 31 Hutchison MediPharma Limited 32 ImmunoGen, Inc. 33 Immunomedics, Inc. 34 Incyte Corporation 35 Infinity Pharmaceuticals, Inc. 36 Innate Pharma S.A. 37 Juno Therapeutics Inc. 38 Karyopharm Therapeutics, Inc. 39 Les Laboratoires Servier SAS 40 LFB S.A. 41 Lymphocyte Activation Technologies, S.A. 42 Millennium Pharmaceuticals, Inc. 43 MorphoSys AG 44 Novartis AG 45 Oncternal Therapeutics, Inc. 46 Ono Pharmaceutical Co., Ltd. 47 Portola Pharmaceuticals, Inc. 48 Sanofi 49 TG Therapeutics, Inc. 50 Threshold Pharmaceuticals, Inc. 51 Tragara Pharmaceuticals, Inc. 52 Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 53 Assessment by Monotherapy Products 53 Assessment by Combination Products 54 Assessment by Target 55 Assessment by Mechanism of Action 58 Assessment by Route of Administration 61 Assessment by Molecule Type 63 Drug Profiles 65 (INCB-039110 + INCB-040093) - Drug Profile 65 4SC-202 - Drug Profile 66 acalabrutinib - Drug Profile 68 ACP-319 - Drug Profile 71 afuresertib hydrochloride - Drug Profile 72 AGS-67E - Drug Profile 75 AT-7519 - Drug Profile 77 AZD-6738 - Drug Profile 80 BI-836826 - Drug Profile 82 BMS-986016 - Drug Profile 83 buparlisib hydrochloride - Drug Profile 84 CC-122 - Drug Profile 88 Cellular Immunotherapy for Chronic Lymphocytic Leukemia - Drug Profile 90 Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 91 cerdulatinib - Drug Profile 92 duvelisib - Drug Profile 94 evofosfamide - Drug Profile 97 HMPL-523 - Drug Profile 104 IMGN-529 - Drug Profile 105 IMMU-114 - Drug Profile 107 JCAR-014 - Drug Profile 108 JCAR-015 - Drug Profile 109 lirilumab - Drug Profile 111 monalizumab - Drug Profile 113 MOR-208 - Drug Profile 115 nivolumab - Drug Profile 117 obinutuzumab - Drug Profile 125 otlertuzumab - Drug Profile 129 pilaralisib - Drug Profile 131 PNK-007 - Drug Profile 134 S-055746 - Drug Profile 135 sapacitabine - Drug Profile 136 selinexor - Drug Profile 138 spebrutinib besylate - Drug Profile 144 TAK-659 - Drug Profile 146 TG-02 - Drug Profile 147 TGR-1202 - Drug Profile 150 tisagenlecleucel-T - Drug Profile 153 ublituximab - Drug Profile 156 UC-961 - Drug Profile 159 ulocuplumab - Drug Profile 160 urelumab - Drug Profile 162 venetoclax - Drug Profile 164 Relapsed Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 168 Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 260 Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 261 Relapsed Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 262 Featured News & Press Releases 262 Appendix 270 Methodology 270 Coverage 270 Secondary Research 270 Primary Research 270 Expert Panel Validation 270 Contact Us 270 Disclaimer 271
List of Tables
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2016 12 Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Development by Companies, H1 2016 (Contd..2) 22 Products under Investigation by Universities/Institutes, H1 2016 23 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2016 24 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2016 25 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H1 2016 26 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 27 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2016 28 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 29 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2016 30 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2016 31 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 32 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H1 2016 33 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 34 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H1 2016 35 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H1 2016 36 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H1 2016 37 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H1 2016 38 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 39 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H1 2016 40 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H1 2016 41 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 42 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2016 43 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H1 2016 44 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H1 2016 45 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 46 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2016 47 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2016 48 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H1 2016 49 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 50 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 51 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2016 52 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H1 2016 53 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 54 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 55 Assessment by Monotherapy Products, H1 2016 56 Assessment by Combination Products, H1 2016 57 Number of Products by Stage and Target, H1 2016 59 Number of Products by Stage and Mechanism of Action, H1 2016 62 Number of Products by Stage and Route of Administration, H1 2016 65 Number of Products by Stage and Molecule Type, H1 2016 67 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2016 171 Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2016 263 Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2016 264


List of Figures
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2016 12 Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Assessment by Monotherapy Products, H1 2016 56 Number of Products by Top 10 Targets, H1 2016 58 Number of Products by Stage and Top 10 Targets, H1 2016 58 Number of Products by Top 10 Mechanism of Actions, H1 2016 61 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 61 Number of Products by Routes of Administration, H1 2016 64 Number of Products by Stage and Routes of Administration, H1 2016 64 Number of Products by Molecule Types, H1 2016 66 Number of Products by Stage and Molecule Types, H1 2016 66

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify